Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

A majority of pharma and biotech companies have a significant ... beating its benchmark by 218 percentage points (see more details here). Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical ...

"Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia" was originally created and published by Pharmaceutical ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

“Biogen has been a foundational presence in ... a 600,000-square-foot research and development center for Japanese pharmaceutical giant Takeda — the state’s biggest biopharma employer ...